Principal Financial Group Inc. grew its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 4.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 296,732 shares of the specialty pharmaceutical company's stock after acquiring an additional 11,321 shares during the period. Principal Financial Group Inc. owned about 0.54% of Supernus Pharmaceuticals worth $10,730,000 as of its most recent filing with the SEC.
Other large investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company's stock worth $61,000 after purchasing an additional 352 shares during the period. Rice Hall James & Associates LLC raised its stake in Supernus Pharmaceuticals by 7.6% during the third quarter. Rice Hall James & Associates LLC now owns 540,788 shares of the specialty pharmaceutical company's stock worth $16,862,000 after acquiring an additional 38,202 shares during the period. Stephens Investment Management Group LLC increased its position in Supernus Pharmaceuticals by 1.8% in the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company's stock valued at $60,246,000 after acquiring an additional 33,710 shares during the period. James Investment Research Inc. lifted its stake in Supernus Pharmaceuticals by 39.8% during the third quarter. James Investment Research Inc. now owns 17,644 shares of the specialty pharmaceutical company's stock valued at $550,000 after buying an additional 5,022 shares in the last quarter. Finally, QRG Capital Management Inc. lifted its position in Supernus Pharmaceuticals by 6.2% in the 3rd quarter. QRG Capital Management Inc. now owns 16,801 shares of the specialty pharmaceutical company's stock worth $524,000 after buying an additional 986 shares in the last quarter.
Insider Buying and Selling
In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the business's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock worth $440,263 over the last ninety days. 9.30% of the stock is owned by corporate insiders.
Supernus Pharmaceuticals Trading Down 0.7 %
NASDAQ SUPN traded down $0.23 during trading hours on Tuesday, hitting $31.51. The company's stock had a trading volume of 396,084 shares, compared to its average volume of 499,137. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The company's 50-day simple moving average is $37.04 and its two-hundred day simple moving average is $35.35. The company has a market capitalization of $1.76 billion, a PE ratio of 29.49 and a beta of 0.90.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on SUPN. StockNews.com cut shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.
Check Out Our Latest Analysis on Supernus Pharmaceuticals
About Supernus Pharmaceuticals
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Featured Articles
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
